Molecular Partners AG
MOLN
View Detailed Chart
4.680USD
+0.654+16.24%
Close 11/06, 16:00（ET）Quotes delayed by 15 min
172.52MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+16.24%
5 Days
+24.14%
1 Month
+24.80%
6 Months
+14.71%
Year to Date
-1.43%
1 Year
-25.00%
View Detailed Chart
TradingKey Stock Score of Molecular Partners AG
Currency: USD Updated: 2025-11-06Key Insights
The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing strongly in the stock market, with strong fundamentals and technicals supporting the momentum. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Molecular Partners AG's Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
4
analysts
Buy
Current Rating
13.541
Target Price
+236.33%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Molecular Partners AG Highlights
StrengthsRisks
Molecular Partners AG is a Switzerland-based clinical-stage biotech company developing DARPin (Designed Ankyrin Repeat Proteins) a new class of custom-built protein therapeutics based on natural binding proteins that open a new dimension of multi-functionality and multi-target specificity in drug design. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.
Growing
The company is in a growing phase, with the latest annual income totaling USD 5.63M.
Fairly Valued
The company’s latest PE is -2.08, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 3.59M shares, decreasing 0.65% quarter-over-quarter.
Molecular Partners AG News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Molecular Partners AG Info
Molecular Partners AG is a Switzerland-based clinical-stage biotech company developing DARPin (Designed Ankyrin Repeat Proteins) a new class of custom-built protein therapeutics based on natural binding proteins that open a new dimension of multi-functionality and multi-target specificity in drug design. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.
Ticker SymbolMOLN
CompanyMolecular Partners AG
CEODr. Patrick Amstutz, Ph.D.
Websitehttps://www.molecularpartners.com/
Related Instruments
+1.26%
+0.52%
+1.05%
+3.23%
+0.85%
+1.65%
-1.33%
-4.02%
+0.67%
+0.98%
+1.00%
+1.70%
-0.18%
+0.34%
+0.88%
+1.07%
0.00%
+0.42%
+1.36%
-0.77%Popular Symbols
